Hypertriglyceridemia: New insights and new approaches to pharmacologic therapy

American Journal of Cardiology

Volumn 87, Issue 10, 2001, Pages 1174-1180

  Ginsberg, Henry N ^a  

^a C ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHYLOMICRON; CLOFIBRATE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HYPOCHOLESTEROLEMIC AGENT; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; PLACEBO; PRAVASTATIN; SIMVASTATIN; VERY LOW DENSITY LIPOPROTEIN;

ATHEROGENESIS; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; COVARIANCE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MECHANISM; EXERCISE; HEART INFARCTION; HUMAN; HYPERTRIGLYCERIDEMIA; INCIDENCE; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPID METABOLISM; LOW FAT DIET; META ANALYSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

EID: 0035873253     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(01)01489-8     Document Type: Note

References (57)

1. Austin M.A. Plasma triglyceride and coronary heart disease. Arterioscler Thromb Vasc Biol. 11:1991;2-14.
2. Triglyceride, high-density lipoprotein, and coronary heart disease. JAMA. 269:1993;505-510.
3. Hokanson J.E., Austin M.A. Plasma triglyceride is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol a meta-analysis of population-based prospective studies . J Cardiovasc Risk. 3:1996;213-219.
4. Austin M.A., Hokanson J.E., Edwards K.L. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 81:1998;7B-12B.
5. Assmann G., Schulte H., von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol. 77:1996;1179-1184.
6. Manninen V., Tenkanen L., Koskinen P., Huttunen J.K., Mänttäri M., Heinonen O.P., Frick M.H. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study implications for treatment . Circulation. 85:1992;37-45.
7. Stampfer M.J., Krauss R.M., Ma J., Blanche P.J., Holl L.G., Sacks F.M., Hennekens C.H. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 276:1996;882-888.
8. Gardner C.D., Fortmann S.P., Krauss R.M. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA. 276:1996;875-881.
9. Miller B.D., Alderman E.L., Haskell W.L., Fair J.M., Krauss R.M. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. Circulation. 94:1996;2146-2153.
10. Lamarche B., Tchernof A., Moorjani S., Cantin B., Dagenais G.R., Lupien P.J., Després J-P. Small, dense low-density lipoprotein particles a predictor of the risk of ischemic heart disease in men prospective results from the Quebec Cardiovascular Study . Circulation. 95:1997;69-75.
11. Jeppesen J., Hein H.O., Suadicani P., Gyntelberg F. Triglyceride concentration and ischemic heart disease an eight-year follow-up in the Copenhagen Male Study . Circulation. 97:1998;1029-1036.
12. Zilversmit D.B. Atherogenic nature of triglycerides, postprandial lipidemia, and triglyceride-rich remnant lipoproteins. Clin Chem. 41:1995;153-158.
13. Vogel R.A., Corretti M.C., Plotnick G.D. Effect of a single high-fat meal on endothelial function in healthy subjects. Am J Cardiol. 79:1997;350-354.
14. Fard A., Tuck C., Donis J.A., Sciacca R., Di Tullio M.R., Wu H., Bryant T.A., Chen N-T., Torres-Tamayo M., Ramasamy R., et al. Plasma asymmetric dimethylarginine levels are acutely elevated and endothelial function is impaired after a high-fat mean in patients with type 2 diabetes. Arterio Thromb Vasc Biol. 20:2000;2039-2044.
15. Ginsberg H.N., Jones J., Blaner W.S., Thomas A., Karmally W., Fields L., Blood D., Begg M.D. Association of postprandial triglyceride and retinyl palmitate responses with newly diagnosed exercise-induced myocardial ischemia in middle-aged men and women. Arterioscler Thromb Vasc Biol. 15:1995;1829-1838.
16. Sharrett A.R., Chambless L.E., Heiss G., Paton C.C., Patsch W. Association of postprandial triglyceride and retinyl palmitate responses with asymptomatic carotid artery atherosclerosis in middle-aged men and women the Atherosclerosis Risk in Communities (ARIC) Study . Arterioscler Thromb Vasc Biol. 15:1995;2122-2129.
17. Austin M.A., King M.C., Vranizan K.M., Krauss R.M. Atherogenic lipoprotein phenotype a proposed genetic marker for coronary heart disease risk . Circulation. 82:1990;495-506.
18. Tribble D.L., van den Berg J.J., Motchnick P.A., Ames B.N., Lewis D.M., Chait A., Krauss R.M. Oxidative susceptibility of low-density lipoprotein subfractions is related to their ubiquinol-10 and alpha-tocopherol content. Proc Natl Acad Sci USA. 91:1994;1183-1187.
19. Camejo G., Hurt-Camejo E., Wiklund O., Bondjers G. Association of apoB lipoproteins with arterial proteoglycans pathological signifcance and molecular basis . Atherosclerosis. 139:1998;205-222.
20. Tall A.R., Jiang X.C., Luo Y., Silver D. George Lyman Duff Memorial Lecture lipid transfer proteins, HDL metabolism, and atherogenesis . Arterioscler Thromb Vasc Biol. 20:2000;1185-1188.
21. Chait A., Albers J.J., Brunzell J.D. Very low density lipoprotein overproduction in genetic forms of hypertriglyceridemia. Eur J Clin Invest. 10:1980;17-22.
22. Kissebah A.H., Alfarsi A., Adams P.W. Integrated regulation for very low density lipoprotein triglyceride and apolipoprotein-B kinetics in man normolipidemic subjects, familial hypertriglyceridemia and familial combined hyperlipidemia . Metabolism. 20:1981;856-868.
23. Arad Y., Ramakrishnan R., Ginsberg H.N. Lovastatin therapy reduces low density lipoprotein apolipoprotein B levels in patients with combined hyperlipidemia by reducing the direct production of low density lipoprotein apolipoprotein B. J Lipid Res. 31:1990;567-582.
24. Kissebah A.H., Alfarsi S., Evans D.J. Low density lipoprotein metabolism in familial combined hyperlipidemia mechanism of the multiple lipoprotein phenotypic expression . Arteriosclerosis. 4:1984;614-624.
25. Janus E.D., Nicoll A., Wootton R., Turner P.R., Magill P.J., Lewis B. Quantitative studies of very low density lipoprotein conversion to low density lipoprotein in normal controls and primary hyperlipidaemic states and the role of direct secretion of low density lipoprotein in heterozygous familial hypercholesterolaemia . Eur J Clin Invest. 10:1980;149-159.
26. Teng B., Sniderman A.D., Soular A.K., Thompson G.R. Metabolic basis of hyperapobetalipoproteinemia turnover of apolipoprotein B in low density lipoprotein and its precursors and subfractions compared with normal and familial hypercholesterolemia . J Clin Invest. 77:1986;663-672.
27. Ginsberg H.N., Ngai C., Wang X-J., Ramakvishnan R. Increased production rates of low-density lipoproteins are common in individuals with low plasma levels of high-density lipoprotein cholesterol, independent of plasma triglyceride concentrations. Arterioscler Thromb Vasc Biol. 13:1993;842-851.
28. Packard C.J., Demant T., Stewart J.P., Bedford D., Casslake M.J., Schwertfeger G., Bedynek A., Shepherd J., Seidel D. Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. J Lipid Res. 41:2000;305-318.
29. Reaven G.M. Role of insulin resistance in human disease. Diabetes. 37:1988;1595-1607.
30. Laws A., Reaven G.M. Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations. J Intern Med. 231:1992;25-30.
31. Després J-P., Lamarche B., Mauriège P., Cantin B., Dagenais G.R., Moorjani S., Lupien P-J. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 334:1996;952-957.
32. Welborn T.A., Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care. 2:1979;154-160.
33. Pyoralla K., Savolainen E., Kaukola S., Haapakoski J. Plasma insulin as coronary heart disease risk factor relationship to other risk factors and predictive value during 9 1/2 year follow-up of the Helsinki Policemen Study Population . Acta Med Scand. 701:(suppl):1985;38-52.
34. Austin M.A., Mykkanen L., Kuusisto J., Edwards K.L., Nelson C., Haffner S.M., Pyörälä K., Laakso M. Prospective study of small LDLs as a risk factor for non-insulin dependent diabetes mellitus in elderly men and women. Circulation. 92:1995;1770-1778.
35. Reaven G.M., Chen Y.D., Jeppesen J., Maheux P., Krauss R.M. Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles. J Clin Invest. 92:1993;141-146.
36. Grundy S.M., Vega G.L. Two different views of the relationship of hypertriglyceridemia to coronary heart disease implications for treatment . Arch Intern Med. 152:1992;28-34.
37. Second report of the Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Circulation. 89:1994;1333-1445.
38. Ginsberg H.N. Is hypertriglyceridemia a risk factor for atherosclerotic cardiovascular disease? A simple question with a complicated answer. Ann Intern Med. 126:1997;912-914.
39. Clofibrate and niacin in coronary heart disease. JAMA. 231:1975;360-381.
40. Blankenhorn D.H., Nessim S.A., Johnson R.L., Sanmarco M.E., Azen S.P., Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 19:(257):1987;3233-3240.
41. Brown G., Albers J.J., Fisher L.D., Schaefer S.M., Lin J-T., Kaplan C., Zhao X.Q., Bisson B.D., Fitzpatrick V.F., Dodge H.T. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 323:1990;1289-1298.
42. Frick M.H., Elo H., Haapa K., Heinonen O.P., Heinsalmi P., Helo P., Huttunen J.K., Kaitaniemi P., Koskinen P., Manninen V., et al. Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 317:1987;1237-1245.
43. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., Faas F.H., Linares E., Schaefer E.J., Schectman G., Wilt T.J., Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 341:1999;410-418.
44. Grundy S.M. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation. 95:1997;1-4.
45. Bakker-Arkema R.G., Davidson M.H., Goldstein R.J., Davignon J., Isaacsohn J.L., Weiss S.R., Keilson L.M., Brown W.V., Miller V.T., Shurzinske L.J., Black D.M. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 275:1996;128-133.
46. Davidson M.H., Stein E.A., Dujovne C.A., Hunninghake D.B., Weiss S.R., Knopp R.H., Illingworth D.R., Mitchel Y.B., Melino M.R., Zupkis R.V., Dobrinska M.R., Amin R.D., Tobert J.A. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol. 79:1997;38-42.
47. Jones P., Kafonek S., Laurora I., Hunninghake D.B. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES Study). Am J Cardiol. 81:1998;582-587.
48. Stein E.A., Lane M., Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol. 81:1998;66B-69B.
49. Ooi T.C., Heinonen T., Alaupovic P., Davignon J., Leiter L., Lupien P.J., Sniderman A.D., Tan M.H., Tremblay G., Soisky A., Shurzinske L., Black D.M. Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia comparison with fenofibrate . Arterioscler Thromb Vasc Biol. 17:1997;1793-1799.
50. Tikkanen M.J., Laakso M., Ilmonen M., Helve E., Kaarsalo E., Kilkki E., Saltevo J. Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM a multicenter comparison study . Diabetes Care. 21:1998;477-481.
51. East C., Bilheimer D.W., Grundy S.M. Combination drug therapy for familial combined hyperlipidemia. Ann Intern Med. 109:1988;25-32.
52. Illingworth D.F., Bacon S. Influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia. Circulation. 79:1989;590-596.
53. Ellen R.L.B., McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol. 81:1998;60B-65B.
54. Shepherd J. Fibrates and statins in the treatment of hyperlipidaemia an appraisal of their efficacy and safety . Eur Heart J. 16:1995;5-13.
55. Carlson L.A., Rosenhamer G. Reduction in mortality in the Stockholm Ischemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 223:1988;405-418.
56. Management of dyslipidemia in adults with diabetes. Diabetes Care. 23:2000;557-565.
57. Assmann G., Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol. 70:1992;733-737.